Zhi Hong, Brii Bio CEO (file photo)

July 13, 2021 10:32 AM EDTUpdated 10:49 AM

Baptized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to carry on with pipeline for infectious diseases and beyond

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

US warns drugmakers against misrepresenting cost of imported products

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?